Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paul Buck joins CNS Response

This article was originally published in Clinica

Executive Summary

EEG biomarker firm CNS Response has made Paul Buck chief financial officer. Mr Buck was previously an independent financial consultant, and has worked with CNS in this capacity since December 2008. Before this, from 1998 to 2003, he was employed by the American Red Cross Biomedical Services as CFO and director of operations for the Southern California region. In his new role, Mr Buck will be responsible for all financial aspects of the company including accounting oversight, financial reporting and analysis, and budgeting. CNS Response (Aliso Viejo, California) analyses EEG signatures to predict treatment responses in patients with CNS disorders, such as depression, anxiety and schizophrenia.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT045513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel